Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC).

被引：0
|
作者：
Balar, Arjun Vasant
Funt, Samuel Aaron
Gupta, Shilpa
Dudek, Arkadiusz Z.
Boiles, Alejandro Recio
Vaena, Daniel A.
Kilari, Deepak
Rosenberg, Jonathan E.
机构：
[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Univ Minnesota, Masonic Canc Ctr, Dept Med, Minneapolis, MN USA
[4] Univ Arizona, Coll Med, Tucson, AZ USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Mem Sloan Kettering Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5098
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Bao, Weichao
    Zhou, Yinghui
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
    Sonpavde, Guru
    Maughan, Benjamin Louis
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Kilbridge, Kerry L.
    Lee, Richard J.
    Yu, Evan
    Schweizer, Michael Thomas
    Montgomery, Robert B.
    Cheng, Heather H.
    Hsieh, Andrew Caleb
    Birhiray, Ruemu E.
    Gabrail, Nashat Y.
    Nemunaitis, John J.
    Rezazadeh, Arash
    Van Veldhuizen, Peter J.
    Vogelzang, Nicholas J.
    Heery, Christopher Ryan
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).
    Natesan, Divya V.
    Zhang, Li
    Oh, David Yoonsuk
    Porten, Sima P.
    Meng, Maxwell
    Pruthi, Raj
    Cooperberg, Matthew R.
    Carroll, Peter
    Chou, Jonathan
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Kwon, Daniel H.
    Wong, Anthony C.
    Feng, Felix Y.
    Aggarwal, Rahul Raj
    Small, Eric Jay
    Fong, Lawrence
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
    Huddart, Robert A.
    Siefker-Radtke, Arlene O.
    Balar, Arjun, V
    Bilen, Mehmet A.
    Powles, Thomas
    Bamias, Aristotelis
    Castellano, Daniel
    Khalil, Maged F.
    van der Heijden, Michiel S.
    Koshkin, Vadim S.
    Pook, David W.
    Ozguroglu, Mustafa
    Santiago, Linda
    Zhong, Bob
    Chien, David
    Lin, Wei
    Tagliaferri, Mary A.
    Loriot, Yohann
    FUTURE ONCOLOGY, 2020, 17 (02) : 137 - 149
  • [6] IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
    Atkins, Michael B.
    McDermott, David F.
    Powles, Thomas
    Motzer, Robert J.
    Rini, Brian I.
    Fong, Lawrence
    Joseph, Richard Wayne
    Pal, Sumanta K.
    Sznol, Mario
    Hainsworth, John D.
    Stadler, Walter Michael
    Hutson, Thomas E.
    Ravaud, Alain
    Bracarda, Sergio
    Suarez, Cristina
    Choueiri, Toni K.
    Qiu, Jiaheng
    Huseni, Mahrukh A.
    Schiff, Christina
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Rosenberg, J. E.
    Bajorin, D. F.
    Smith, A.
    D'Cruz, C.
    Lanasa, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
    He, Aiwu Ruth
    Kim, Alexander Y.
    Toskich, Beau M.
    Mody, Kabir
    Kim, Kevin
    Stein, Stacey
    Goyal, Lipika
    Abrams, Thomas Adam
    Brown, Daniel
    Goff, Laura Williams
    Kim, Richard D.
    Parikh, Nainesh
    Sandow, Tyler
    Johnson, Daniel
    Iyer, Renuka V.
    Petroziello, Michael
    Krishnamurthi, Smitha S.
    Martin, Charles
    Jiang Yixing
    Akhter, Nabeel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [9] Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Piciu, Ana-Maria
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
    Rosenberg, J.
    Necchi, A.
    Sweis, R. F.
    Nakajima, K.
    Lu, C.
    Nogai, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 329 - 329
12345